Helmchen, Christoph
Wandinger, Klaus-Peter
Steffen, Armin
Münte, Thomas F.
Brüggemann, Norbert
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 19 August 2020
Revised: 30 September 2020
Accepted: 21 December 2020
First Online: 23 January 2021
Compliance with ethical standards
:
: C. Helmchen received honoraria from Sensorion, Heel, Schwabe, Pierre Fabre. K.P.Wandinger reports no disclosures relevant to the manuscript; A. Steffen is a study investigator and received honoraria and travel expenses for invited talks on behalf of Inspire Medical, Inc. He serves as a consultant for Merz Pharmaceuticals and received honoraria for expert meetings from Proveca Ltd. T.F. Münte is funded by the DFG (MU1311/16-2, 17-1, 20-1, CRC/TR296) and BMBF (01GJ1303B). N. Brüggemann received speaker’s honoraria from Grünenthal, UCB, Abbvie and Teva. He served as a consultant for Censa Pharmaceuticals and Centogene. He received non-financial support from Bayer. NB is funded by the DFG (BR4328.2-2, GRK1957), the Collaborative Center for X-linked Dystonia-Parkinsonism and the Else-Kröner Fresenius-Stiftung (HA17_2017).
: The authors assure that the work was conducted in line with the ethical standards of the Journal of Neurology.